Redsense Medical arranged Congressional Briefing to address Venous Needle Dislodgement
The briefing was held on September 27, 2023 in the Rayburn House Office Building, Washington DC with the purpose to bring together various stakeholders in the renal area to share knowledge, experience and discuss risks with Venous Needle Dislodgement (VND) and how to increase patient safety for hemodialysis patients.
In addition to Redsense, The American Association of Kidney Patients (AAKP) and Emergency Care Research Institute (ECRI) presented during the briefing. AAKP is the oldest and largest independent kidney patient organization and in the United States and ECRI is a global independent, non-profit organization devoted to improving safety, quality, and cost-effectiveness of care across all healthcare settings. Presenting on behalf of Redsense was the company’s US Clinical Director Jane Hurst.
This event gave members of the Congress an opportunity to learn more about the real risks with VND, its serious consequences and what can be done to address these concerns through enactment of the Home Dialysis Risk Prevention Act (H.R. 3118), introduced by Rep. Adrian Smith (R-NE) and Rep. Melaine Stansbury (D-NM).
“It is well proven that home hemodialysis means better clinical outcome and higher quality of life for patients, and we are pleased that the Home Dialysis Risk Prevention Act is addressing the need for Medicare coverage of monitoring devices to detect and alarm when a VND occurs during home hemodialysis. We look forward to the advancement of this legislation and to continue contributing to increased patient safety for home hemodialysis” says Pontus Nobréus, CEO of Redsense Medical.
About venous needle dislodgement (VND)
During hemodialysis, the patient’s bloodstream is connected to an artificial kidney machine outside of the body using vascular access. The purified blood is returned to the patient through venous needle access. If the venous needle dislodges, the patient loses a lot of blood quickly if it is not immediately detected. Unpredictable VND can happen to any dialysis patient, at any time. VND has been estimated to occur more than 300 times a day in the United States alone and poses a serious safety risk for the patient.
Contact information
For more information, please contact:
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector